ASCO GU 2026: Adjuvant Belzutifan + Pembrolizumab Reduces Risk of Recurrence or Death in ccRCC

Adjuvant pembrolizumab plus belzutifan may represent a new standard of care for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, as the LITESPARK-022 trial showed a meaningful reduction in the risk of recurrence or death compared with pembrolizumab alone.